Jean-Frederic Viret - 01 Dec 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
Chief Financial Officer
Signature
Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Dec 2023
Net transactions value
$0
Form type
4
Filing time
04 Dec 2023, 16:27:06 UTC
Previous filing
08 Nov 2023
Next filing
08 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +450,000 $0.000000 450,000 01 Dec 2023 Common Stock 450,000 $0.7700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest over a four-year period commencing November 3, 2023, with 1/4th of the shares vesting on November 3, 2024 and 1/48th of the shares vesting monthly thereafter.